Cargando…

c-Kit Induces Migration of Triple-Negative Breast Cancer Cells and Is a Promising Target for Tyrosine Kinase Inhibitor Treatment

Triple-negative breast cancer (TNBC) is associated with a poor prognosis and the absence of targeted therapy. c-Kit, a receptor tyrosine kinase (RTK), is considered a molecular target for anticancer drugs. Tyrosine kinase inhibitors (TKIs) recognizing c-Kit are used for the treatment of c-Kit-expres...

Descripción completa

Detalles Bibliográficos
Autores principales:	López-Mejía, José A., Tallabs-Utrilla, Luis F., Salazar-Sojo, Pablo, Mantilla-Ollarves, Jessica C., Sánchez-Carballido, Manuel A., Rocha-Zavaleta, Leticia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9369219/ https://www.ncbi.nlm.nih.gov/pubmed/35955836 http://dx.doi.org/10.3390/ijms23158702

Ejemplares similares

Modulation of JAK-STAT Signaling by LNK: A Forgotten Oncogenic Pathway in Hormone Receptor-Positive Breast Cancer
por: López-Mejía, José A., et al.
Publicado: (2023)

Biological Landscape of Triple Negative Breast Cancers Expressing CTLA-4
por: Navarrete-Bernal, María G. C., et al.
Publicado: (2020)

Allosteric Communication across the Native and Mutated KIT Receptor Tyrosine Kinase
por: Laine, Elodie, et al.
Publicado: (2012)

The Pan‐Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA
por: Disel, Umut, et al.
Publicado: (2019)

Assessing the Activation of Tyrosine Kinase KIT through Free Energy Calculations
por: Sandoval-Pérez, Angélica, et al.
Publicado: (2022)

Expression of KIT Receptor Tyrosine Kinase in Endothelial Cells of Juvenile Brain Tumors
por: Puputti, Marjut, et al.
Publicado: (2009)

The Inherent Coupling of Intrinsically Disordered Regions in the Multidomain Receptor Tyrosine Kinase KIT
por: Ledoux, Julie, et al.
Publicado: (2022)

Role and significance of c-KIT receptor tyrosine kinase in cancer: A review
por: Sheikh, Emana, et al.
Publicado: (2022)

Correction to “Assessing the Activation of Tyrosine Kinase KIT through Free Energy Calculations”
por: Sandoval-Pérez, Angélica, et al.
Publicado: (2022)

Mechanism of immune escape mediated by receptor tyrosine kinase KIT in thyroid cancer
por: Luo, Zhen, et al.
Publicado: (2023)

Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT
por: Dubreuil, Patrice, et al.
Publicado: (2009)

Tyrosine Kinase Inhibitors Induce Down-Regulation of c-Kit by Targeting the ATP Pocket
por: D'allard, Diane, et al.
Publicado: (2013)

Mutated KIT Tyrosine Kinase as a Novel Molecular Target in Acute Myeloid Leukemia
por: Katagiri, Seiichiro, et al.
Publicado: (2022)

Transcriptomic Analysis of Subtype-Specific Tyrosine Kinases as Triple Negative Breast Cancer Biomarkers
por: Limsakul, Praopim, et al.
Publicado: (2023)

The Three Receptor Tyrosine Kinases c-KIT, VEGFR2 and PDGFRα, Closely Spaced at 4q12, Show Increased Protein Expression in Triple-Negative Breast Cancer
por: Jansson, Sara, et al.
Publicado: (2014)

Does Generic Cyclic Kinase Insert Domain of Receptor Tyrosine Kinase KIT Clone Its Native Homologue?
por: Ledoux, Julie, et al.
Publicado: (2022)

Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells
por: Abbaspour Babaei, Maryam, et al.
Publicado: (2016)

Oncogenic signaling by Kit tyrosine kinase occurs selectively on the Golgi apparatus in gastrointestinal stromal tumors
por: Obata, Y, et al.
Publicado: (2017)

KIT-Associated Familial GIST Syndrome: Response to Tyrosine Kinase Inhibitors and Implications for Risk Management
por: Brodey, Alexandra, et al.
Publicado: (2022)

Bruton's Tyrosine Kinase: A Promising Target for the Treatment of COVID-19
por: Rezaei, Mitra, et al.
Publicado: (2020)

Genetic analysis reveals cell type-specific regulation of receptor tyrosine kinase c-Kit by the protein tyrosine phosphatase SHP1
Publicado: (1996)

Selecting Tyrosine Kinase Inhibitors for Gastrointestinal Stromal Tumor with Secondary KIT Activation-Loop Domain Mutations
por: Hsueh, Yuan-Shuo, et al.
Publicado: (2013)

Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
por: Serrano, César, et al.
Publicado: (2019)

Metallopeptidase inhibitor 1 (TIMP‐1) promotes receptor tyrosine kinase c‐Kit signaling in colorectal cancer
por: Nordgaard, Cathrine, et al.
Publicado: (2019)

Folding and Intrinsic Disorder of the Receptor Tyrosine Kinase KIT Insert Domain Seen by Conventional Molecular Dynamics Simulations
por: Ledoux, Julie, et al.
Publicado: (2021)

Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways
por: Wu, Xinyan, et al.
Publicado: (2015)

The tyrosine kinase inhibitor nintedanib activates SHP-1 and induces apoptosis in triple-negative breast cancer cells
por: Liu, Chun-Yu, et al.
Publicado: (2017)

A Tyrosine Kinase Expression Signature Predicts the Post-Operative Clinical Outcome in Triple Negative Breast Cancers
por: de Nonneville, Alexandre, et al.
Publicado: (2019)

Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer
por: Guerrab, Abderrahim El, et al.
Publicado: (2016)

Phytochemicals inhibit migration of triple negative breast cancer cells by targeting kinase signaling
por: Shahi Thakuri, Pradip, et al.
Publicado: (2020)

Primary breast cancer cell culture yields intra-tumor heterogeneous subpopulations expressing exclusive patterns of receptor tyrosine kinases
por: Esparza-López, José, et al.
Publicado: (2016)

Small-Molecule Inhibitors of the Receptor Tyrosine Kinases: Promising Tools for Targeted Cancer Therapies
por: Hojjat-Farsangi, Mohammad
Publicado: (2014)

Src-family Protein Tyrosine Kinases: A promising target for treating Cardiovascular Diseases
por: Zhai, Yuhong, et al.
Publicado: (2021)

The receptor tyrosine kinase AXL promotes migration and invasion in colorectal cancer
por: Uribe, Diana J., et al.
Publicado: (2017)

Acute motor neuropathy with quadriparesis following treatment with triple tyrosine kinase inhibitor, nintedanib
por: Kunadu, Afua, et al.
Publicado: (2021)

Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?
por: Massard, C, et al.
Publicado: (2007)

Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?
por: Massard, C, et al.
Publicado: (2008)

Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
por: Serrano, César, et al.
Publicado: (2019)

Receptor tyrosine kinase C-kit promotes a destructive phenotype of FLS in osteoarthritis via intracellular EMT signaling
por: Cao, Xu, et al.
Publicado: (2023)

ABL Tyrosine Kinase Inhibition Variable Effects on the Invasive Properties of Different Triple Negative Breast Cancer Cell Lines
por: Chevalier, Clément, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_kaphet60n81huqmdjf1t6qt40e